DGAP-Adhoc: MOLOGEN AG resolves capital increase from authorized capital


MOLOGEN AG  / Key word(s): Capital Increase

05.02.2014 21:47

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

With the approval of the Supervisory Board and on the basis of the
registered authorized capital the Management Board of MOLOGEN AG decided
today to increase the share capital against cash contributions without
subscription rights of the shareholders from currently EUR 15,419,512 to
EUR 16,960,756 Euros by issuing up to 1,541,244 new no-par value bearer
shares with dividend rights from 1st January 2013. The proceeds from the
capital increase will be used to further strengthen the equity base and in
particular to finance the development of the product pipeline and the
necessary ongoing research operations.

The new shares will be offered to European qualified investors in the
context of a private placement. The placement starts today, 5 February
2014, and is expected to be completed tomorrow, 6 February 2014. MOLOGEN AG
will set the issue price after the completion of a bookbuilding process and
depending on the market situation at a discount of up to 5 per cent on the
volume weighted average share price in Xetra trading during the last five
trading days or on the in XETRA trading lastly determined stock price. The
new shares shall be admitted to trading, without prospectus requirement, in
the sub-segment of the regulated market with further post-admission
obligations (Prime Standard) of the Frankfurt Stock Exchange.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

DISCLAIMER

This document is not an offer of securities for sale in the United States
of America. The securities have not been and will not be registered under
the U.S. Securities Act of 1933, as amended (the 'Securities Act') and may
not be offered or sold absent registration or an exemption from
registration under the Securities Act. The Issuer does not intend to
register any portion of the offering in the United States of America or to
conduct a public offering of the securities in the United States of
America, Canada, Australia, Japan or South Africa.


About MOLOGEN AG 

MOLOGEN AG is a publicly listed biotechnology company headquartered in
Berlin and specializes in the research and clinical development of
innovative drugs in the fields of oncology and infectious diseases. One of
the company's most important product candidates is the DNA immunomodulator
MGN1703, which is being clinically developed for colorectal cancer and lung
cancer. The cell-based cancer therapy MGN1601 for the treatment of renal
cancer is also currently at the stage of clinical development.

With
unique, patented technologies and innovative product developments, MOLOGEN
is one of the leading biotechnology companies in the fields of DNA medicine
and cell-based therapies.

MOLOGEN AG shares (ISIN DE0006637200) are listed
in the Prime Standard of the German Stock Exchange.

www.mologen.com 


Memberships in associations:

Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. 
|  DECHEMA - Society for chemical technology and biotechnology e.V.  | 
German industrial association of biotechnology (DIB)  |  Association for
the Promotion of Science and Humanities in Germany  |  Association of
German biotechnology companies (VBU)  |  Association of researching
manufacturers of pharmaceuticals e.V. (VFA)  |  Association of the chemical
industry e.V. (VCI)

MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.


MOLOGEN AG

PRESS SERVICE:
Prof. Peter W. Hübner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
huebner@mologen.com

INVESTOR RELATIONS:
Jörg Petraß
Tel: +49 - 30 - 84 17 88 - 13
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com 


External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
Tel: +49 - 40 - 60 91 86 - 18
Fax: +49 - 40 - 60 91 86 - 16
sebastian.bucher@kirchhoff.de 

05.02.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      MOLOGEN AG
              Fabeckstraße 30
              14195 Berlin
              Germany
Phone:        030 / 841788-0
Fax:          030 / 841788-50
E-mail:       info@mologen.com
Internet:     www.mologen.com
ISIN:         DE0006637200
WKN:          663720
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------